Legal Proceedings Report • Nov 27, 2017
Legal Proceedings Report
Open in ViewerOpens in native device viewer
Bergen, Norway, 27 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, provides an update on BGBC004, an on-going, company sponsored US study evaluating BGB324 in conjunction with TARCEVA® (erlotinib) in patients with non-small cell lung cancer, in response to recent media coverage.
BerGenBio gained the required approvals from the US Food & Drug Administration (FDA) and from the ethics committees at the participating US hospitals prior to starting this study with BGB324. BerGenBio can confirm that it is in discussions with the Regional Ethics Committee (REK) in Bergen and the Norwegian Board of Health to gain retrospective approval to conduct the BGBC004 study in the US.
Contact Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 Tom Henrik Sundby Finance Director, BerGenBio ASA [email protected] +47 477 54 415 Media Relations David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson
+44 207 638 9571
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.